AIDS Therapy

Study supports value of resistance tests to guide use of newer HIV drugs

Published in Biotech Business Week, May 19th, 2003

ViroLogic, Inc., (VLGC) announced that results of a recent study support the utility of its proprietary drug resistance assays to guide HIV/AIDS treatment with regimens containing the recently marketed protease inhibitors (PIs), lopinavir (Kaletra) or amprenavir (Agenerase).

By analyzing phenotypic and genotypic assay results from more than 1000 HIV samples in ViroLogic's proprietary database, company researchers developed an improved, comprehensive scoring system for interpreting genotypic results. ViroLogic identified known and new mutations responsible for resistance to lopinavir and demonstrated that cross-resistance between lopinavir and amprenavir may be more...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2003-05-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry